Compare ACRE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | WHWK |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 164.8M |
| IPO Year | 2011 | 2017 |
| Metric | ACRE | WHWK |
|---|---|---|
| Price | $3.31 | $3.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $5.00 | ★ $7.71 |
| AVG Volume (30 Days) | ★ 633.7K | 292.4K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 17.39% | N/A |
| EPS Growth | 26.17 | ★ 86.02 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.86 | N/A |
| P/E Ratio | $2.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.44 | $1.97 |
| 52 Week High | $5.89 | $5.50 |
| Indicator | ACRE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 21.52 | 27.79 |
| Support Level | N/A | $2.46 |
| Resistance Level | $5.37 | $3.05 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 0.68 | 13.64 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.